



I hereby Certify that this Correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on April 22, 2004

Susan L. Eick

Susan L. Eick

Signature
April 22, 2004
Date of Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ferrone et al.

Filed: July 11, 2003

Serial No. 10/618,336

For: GD3 Peptide Mimics

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant wishes to make of record the references listed in the attached Form 1449. Legible copies of the references listed are enclosed.

It is believed that no fee is due. However, if that is incorrect, the Examiner is authorized to charge any fee due to Deposit Account No. 08-2442.

Respectfully submitted,

By: _____

Ranjana Kadle, Reg. No. 40,041

HODGSON RUSS LLP
One M & T Plaza, Suite 2000
Buffalo, New York 14203-2391
Tel: (716) 848-1628
Dated: April 22, 2004



APR 26 2004

Please type \oplus plus sign inside this box +

PTO/SB/08A(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet 1 of 2

Attorney Documentation 1000 Words

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	03551.0135
-------	---	----	---	------------------------	------------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	²
	1	CHAPMAN ET AL., <i>Vaccination with a Bivalent G_{M2} and G_{D2} Ganglioside Conjugate Vaccine: A Trial Comparing Doses of G_{D2}-Keyhole</i> , Clinical Cancer Research (December 2000) Vol. 6, pp. 4658-4662	
	2	GRANT ET AL., <i>Long Survival of Patients with Small Cell Lung Cancer after Adjuvant Treatment with the Anti-Idiotypic Antibody BEC2 Plus Bacillus Calmette-Guérin</i> , Clinical Cancer Research (June 1999) Vol. 5, pp. 1319-1323	
	3	LESINSKI ET AL., <i>A DNA Vaccine Encoding a Peptide Mimic of Streptococcus Pneumoniae Serotype 4 Capsular Polysaccharide Induces Specific Anti-Carbohydrate Antibodies in Balb/c Mice</i> , Vaccine (2001) Vol. 19, pp. 1717-1726	
	4	LUO ET AL., <i>A Molecular Basis for Functional Peptide Mimicry of a Carbohydrate Antigen</i> , The Journal of Biological Chemistry (May 26, 2000) Vol. 275, No. 21, pp. 16146-16154	
	5	MCCAFFERY ET AL., <i>Immunization of Melanoma Patients with BEC2 Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside: Enhanced Immunogenicity When Combined with Adjuvant</i> , Clinical Cancer Research (April 1996) Vol. 2, pp. 679-686	
	6	QIU ET AL., <i>Towards the Development of Peptide Mimotopes of Carbohydrate Antigens as Cancer Vaccines</i> , Hybridoma (1999) Vol. 18, No. 1, pp. 103-112	
	7	YAO ET AL., <i>Immunization of Melanoma Patients with BEC2-Keyhole Limpet Hemocyanin Plus BCG Intradermally Followed by Intravenous Booster Immunizations with BEC2 to Induce Anti-GD3 Ganglioside Antibodies</i> , Clinical Cancer Research (January 1999) Vol. 5, pp. 77-81	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.